Protective Cell-Mediated Immunity Against Lethal H5N1 Influenza A Viruses
针对致命性 H5N1 甲型流感病毒的保护性细胞介导的免疫
基本信息
- 批准号:7232680
- 负责人:
- 金额:$ 39.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-06-01 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAnimal ModelAntibodiesAntibody FormationAntibody-mediated protectionAreaBirdsCD4 Positive T LymphocytesCD8B1 geneCellular ImmunityCharacteristicsChildClassConditionDendritic CellsDepthDevelopmentEffectivenessEffector CellEngineeringEpidemiologyEquilibriumFar EastFerretsFormalinFundingGenerationsGenesGovernmentGranzymeGrowthHemagglutininHospitalsHumanHumoral ImmunitiesImmune responseImmunizationImmunologic MonitoringImmunologyInactivated VaccinesInfectionInfection preventionInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza A Virus, H5N1 SubtypeInfluenza A virusInstitutionIntegrinsInterferonsKineticsKnockout MiceKnowledgeLaboratoriesLaboratory AnimalsLeadLicensingLifeMeasuresMediatingMemoryModelingMolecular VirologyMusMutateMutationNatural Killer CellsNatureNeuraminidaseNumbersOnset of illnessOseltamivirOvalbuminPeptidesPhasePopulationPopulation SurveillanceProductionProteinsPublic HealthRangeReagentReassortant VirusesRecoveryResearchResearch PersonnelResponse ElementsSELL geneServicesSeveritiesSeverity of illnessSiteSourceStagingStandards of Weights and MeasuresT memory cellT-Cell ReceptorT-LymphocyteT-Lymphocyte EpitopesTNF geneThinkingTransgenic MiceVaccinesVariantVirulenceVirulentVirusVirus DiseasesWild Type Mouseanti-influenza drugauthoritycell typecross reactivitycytokinedomestic birdenzyme linked immunospot assayimmunogenicimmunopathologyinfluenza virus vaccineinfluenzaviruskillingsmemory recallmouse modelmutantneutralizing antibodypandemic diseaseperforinpositional cloningpreventprogramsprotective effectresearch studyresponsevirus pathogenesis
项目摘要
DESCRIPTION (provided by applicant): All responsible governments are greatly concerned about the possibility that the highly lethal H5N1 influenza A viruses that have been killing large numbers of wild and domestic birds (and a few people) in South East Asia may suddenly change their host range and begin to spread globally, with extreme rapidity, among human populations. Though we have an effective anti-influenza drug (Oseltamivir), a new-generation H5N1 vaccine is in an advanced stage of development, and the influenza virus research, surveillance and public health networks are first class, the capacity of these viruses to mutate very rapidly means that there is no way to be absolutely sure that we will not be hit by a virus against which we relatively little protection. The current formalin-inactivated vaccines promote a highly specific and effective antibody response, provided this is directed against exactly the right virus, but they do not stimulate the more cross-reactive cell-mediated immunity (CMI) that can give some measure of protection against a broad spectrum of influenza A viruses. The question is, should we be thinking about vaccine strategies that also induce virus-specific CD4+ and CD8+ "memory" T cells, in the knowledge that the more rapid emergence of these effectors of CMI will, at best, ameliorate the severity of the disease rather than prevent infection completely? Though it is the case that many people will already have some influenza-specific T cell memory, it is also likely that regular boosting will greatly increase both the numbers of these memory T cells and the rapidity of the recall response following live virus challenge. The present experiments address the effectiveness and characteristics of the CMI response in mice that have (like people) previously been exposed to heterologous influenza A viruses, then infected with these highly virulent H5N1 influenza A viruses. A variety of genetically engineered and reassortant viruses will be used in prime, boost and challenge experiments to investigate the limits of protection and the cellular mechanisms that might be selectively promoted if an effective CMI- directed vaccine were to be developed. Whether the H5N1 viruses have particular characteristics that tend to subvert the protection conferred by pre-existing CMI will also be addressed, in the hope of identifying strategies that might be used to defeat such effects. These studies should allow us to develop a clear, mechanistic understanding of how to promote effective CMI against the H5N1 viruses.
描述(由申请人提供):所有负责任的政府都非常关注在东南亚杀死大量野生和家禽(以及少数人)的高致死性H5N1甲型流感病毒可能突然改变其宿主范围,并开始在全球范围内以极快的速度在人群中传播的可能性。虽然我们有一种有效的抗流感药物(奥司他韦),新一代H5N1疫苗也处于研制的后期阶段,而且流感病毒的研究、监测和公共卫生网络也是一流的,但这些病毒的变异能力非常迅速,这意味着没有办法绝对肯定我们不会受到一种我们相对缺乏保护的病毒的打击。目前的福尔马林灭活疫苗促进高度特异性和有效的抗体应答,只要这是针对正确的病毒,但它们不刺激更具交叉反应性的细胞介导的免疫(CMI),可以提供某种程度的保护,以对抗广谱的流感病毒A。问题是,我们是否应该考虑也诱导病毒特异性CD4+和CD8+“记忆”T细胞的疫苗策略,因为这些CMI效应物的更快出现充其量只能减轻疾病的严重程度,而不是完全预防感染?虽然许多人已经有了一些流感特异性T细胞记忆,但定期加强免疫也可能会大大增加这些记忆T细胞的数量和活病毒攻击后回忆反应的速度。本实验解决了先前暴露于异源甲型流感病毒,然后感染这些高毒力H5N1甲型流感病毒的小鼠(如人)中CMI应答的有效性和特征。将在初免、加强和攻毒实验中使用各种基因工程和抗性病毒,以研究保护的限度和如果要开发有效的CMI导向疫苗可能选择性促进的细胞机制。H5N1病毒是否具有倾向于破坏先前存在的CMI所赋予的保护的特定特征也将被讨论,以期确定可能用于克服这种影响的策略。这些研究应该使我们能够对如何促进针对H5 N1病毒的有效CMI有一个清晰的、机制性的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER C DOHERTY其他文献
PETER C DOHERTY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER C DOHERTY', 18)}}的其他基金
Protective Cell-Mediated Immunity Against Lethal H5N1 Influenza A Viruses
针对致命性 H5N1 甲型流感病毒的保护性细胞介导的免疫
- 批准号:
7426908 - 财政年份:2006
- 资助金额:
$ 39.99万 - 项目类别:
Protective Cell-Mediated Immunity Against Lethal H5N1 Influenza A Viruses
针对致命性 H5N1 甲型流感病毒的保护性细胞介导的免疫
- 批准号:
7129242 - 财政年份:2006
- 资助金额:
$ 39.99万 - 项目类别:
Protective Cell-Mediated Immunity Against Lethal H5N1 Influenza A Viruses
针对致命性 H5N1 甲型流感病毒的保护性细胞介导的免疫
- 批准号:
7849033 - 财政年份:2006
- 资助金额:
$ 39.99万 - 项目类别:
Protective Cell-Mediated Immunity Against Lethal H5N1 Influenza A Viruses
针对致命性 H5N1 甲型流感病毒的保护性细胞介导的免疫
- 批准号:
7622169 - 财政年份:2006
- 资助金额:
$ 39.99万 - 项目类别:
SINGLE CELL ANALYSIS OF A MULTI-TIER AIDS VACCINE
多层艾滋病疫苗的单细胞分析
- 批准号:
6320775 - 财政年份:2000
- 资助金额:
$ 39.99万 - 项目类别:
SINGLE CELL ANALYSIS OF A MULTI-TIER AIDS VACCINE
多层艾滋病疫苗的单细胞分析
- 批准号:
6167468 - 财政年份:1999
- 资助金额:
$ 39.99万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 39.99万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 39.99万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 39.99万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 39.99万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 39.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 39.99万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 39.99万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 39.99万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 39.99万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 39.99万 - 项目类别:
Grant-in-Aid for Early-Career Scientists